Table 1. Demographic and clinical... | American Society of Hematology

Table 1.

Demographic and clinical information for patients with SCD who developed hematologic malignancies after allogeneic HCT

Patient No.	SCD type	Age at HCT, y/sex	SCD comorbidities	HCT type	TBI dose, cGy	PC	PT-Cy dose, mg/kg	Cytos pre-HCT	Day of graft failure	Malignancy	Time of malignancy dx post-HCT, y	Cytos and bone marrow blasts at malignancy dx	DMC at dx	DLC at dx	Current status
1	HbSS	37/male	Recurrent VOC Chronic pain	HLA matched	300	No	0	Normal	183	MDS	2.5	Complex <5%	0	0	Dec
2	HbSS	19/male	Priapism ACS	HLA matched	300	No	0	Normal	N/A	CML	3.5	46XY, t(2, 9, 22), BCR/ABL1 p210 fusion <5%	39	59	Alive
3	HbS-β⁰thal	53/male	TRV 3.2 m/s	HLA matched	300	No	0	ND	N/A	MCL	9	Monosomy 13, 11q deletion and t(11;14) <5%	89	73	Alive
4	HbSS	34/male	TRV 2.5 m/s Priapism ACS Recurrent VOC	HLA matched	300	Yes	0	Normal	74	AML	0.33	Complex 15%-20%	16	18	Dec
5	HbSS	39/female	Silent infarct ACS TRV 2.8 m/s SCD-associated liver disease	HLA matched	300	Yes	0	Normal	N/A	T-cell ALL	3	46XX, t(9:22) [18]/46,XY[2] BCR/ABL1 p190 fusion 93%	30	25	Alive
6	HbSS	37/male	Stroke CRI Recurrent VOC	Haplo	400	No	100	Normal	73	MDS	2	Complex <5%	0	0	Dec
7	HbSS	20/female	Recurrent VOC ACS SCD-associated liver disease Chronic pain	Haplo	400	No	100	Normal	90	AML	5.5	Complex 20%	0	0	Dec
8	HbSS	44/female	ESRD pHTN Diastolic dysfunction	Haplo	400	No	0	Normal	7 mo	AML	5	7q deletion 10%-15%	0	0	Dec

Patient No.	SCD type	Age at HCT, y/sex	SCD comorbidities	HCT type	TBI dose, cGy	PC	PT-Cy dose, mg/kg	Cytos pre-HCT	Day of graft failure	Malignancy	Time of malignancy dx post-HCT, y	Cytos and bone marrow blasts at malignancy dx	DMC at dx	DLC at dx	Current status
1	HbSS	37/male	Recurrent VOC Chronic pain	HLA matched	300	No	0	Normal	183	MDS	2.5	Complex <5%	0	0	Dec
2	HbSS	19/male	Priapism ACS	HLA matched	300	No	0	Normal	N/A	CML	3.5	46XY, t(2, 9, 22), BCR/ABL1 p210 fusion <5%	39	59	Alive
3	HbS-β⁰thal	53/male	TRV 3.2 m/s	HLA matched	300	No	0	ND	N/A	MCL	9	Monosomy 13, 11q deletion and t(11;14) <5%	89	73	Alive
4	HbSS	34/male	TRV 2.5 m/s Priapism ACS Recurrent VOC	HLA matched	300	Yes	0	Normal	74	AML	0.33	Complex 15%-20%	16	18	Dec
5	HbSS	39/female	Silent infarct ACS TRV 2.8 m/s SCD-associated liver disease	HLA matched	300	Yes	0	Normal	N/A	T-cell ALL	3	46XX, t(9:22) [18]/46,XY[2] BCR/ABL1 p190 fusion 93%	30	25	Alive
6	HbSS	37/male	Stroke CRI Recurrent VOC	Haplo	400	No	100	Normal	73	MDS	2	Complex <5%	0	0	Dec
7	HbSS	20/female	Recurrent VOC ACS SCD-associated liver disease Chronic pain	Haplo	400	No	100	Normal	90	AML	5.5	Complex 20%	0	0	Dec
8	HbSS	44/female	ESRD pHTN Diastolic dysfunction	Haplo	400	No	0	Normal	7 mo	AML	5	7q deletion 10%-15%	0	0	Dec

ACS, acute chest syndrome; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CRI, chronic renal insufficiency; Dec, deceased; DLC, donor lymphoid chimerism; DMC, donor myeloid chimerism; dx, diagnosis; ESRD, end-stage renal disease; Haplo, haploidentical; HbS-β⁰thal, compound heterozygosity for hemoglobin S and β 0 thalassemia; HbSS, homozygous SCD; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; N/A, not applicable; ND, not done; pHTN, right heart catheterization-documented pulmonary hypertension; PT-Cy, posttransplant cyclophosphamide; t, translocation; TRV, tricuspid regurgitant velocity; VOC, vaso-occlusive crises.

View Large

This Feature Is Available To Subscribers Only